GO:0051958 methotrexate transport: Drug Transport Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051958 methotrexate transport describes the directed movement of methotrexate, a folic acid analogue and potent dihydrofolate reductase inhibitor, across cellular membranes or within cells via transporters or pores.
• Methotrexate enters cells mainly through the reduced folate carrier (RFC/SLC19A1) and can also be exported by ATP-binding cassette (ABC) transporters such as MRP/ABCC family members.
• Transport activity directly determines methotrexate sensitivity and resistance in cancer and inflammatory diseases, making it a key pharmacological determinant.
• Multiple experimental systems, including human cancer cell lines, Xenopus oocytes, and membrane vesicles, have been used to characterize methotrexate transport kinetics and inhibitor profiles.
• Altered expression or function of methotrexate transporters is linked to drug resistance in leukemia, solid tumors, and inflammatory conditions such as rheumatoid arthritis.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of specific transporters in methotrexate uptake, efflux, and cytotoxicity.
Description
Methotrexate (MTX) is a folate antagonist widely used as an anticancer and immunosuppressive agent. Its clinical efficacy depends critically on its ability to cross cell membranes, a process defined by the Gene Ontology term GO:0051958, methotrexate transport. This term encompasses the directed movement of methotrexate into, out of, or within a cell, mediated by transporters or pores. Understanding the molecular machinery and regulation of methotrexate transport is essential for predicting drug response, overcoming resistance, and designing targeted therapies. Methotrexate is a hydrophilic molecule that cannot freely diffuse across lipid bilayers; therefore, it relies on specialized transport systems. The reduced folate carrier (RFC, SLC19A1) is the primary influx transporter in many cell types, while efflux is often mediated by ATP-binding cassette (ABC) transporters such as multidrug resistance-associated proteins (MRPs/ABCCs). Additional transporters, including folate receptors and organic anion transporters, can contribute to methotrexate uptake in specific tissues. Research on methotrexate transport spans cancer biology, pharmacology, and immunology. Defects in transport are a well-recognized mechanism of methotrexate resistance in leukemia and solid tumors. In inflammatory diseases like rheumatoid arthritis, transport variability influences drug efficacy and toxicity. The availability of diverse cell lines and model systems has enabled detailed kinetic and molecular studies of methotrexate transport.
methotrexate transport At A Glance
| GO ID | GO:0051958 |
|---|---|
| GO term | methotrexate transport |
| Ontology | biological_process |
| Synonym | none |
| Major function | Mediates the directed movement of methotrexate across cellular membranes via transporters or pores |
| Definition source | QuickGO definition based on published literature |
| Related transporters | SLC19A1 (RFC), ABCC1-5 (MRPs), folate receptors, organic anion transporters |
| Physiological relevance | Determines cellular uptake, efflux, and sensitivity to methotrexate in cancer and inflammatory diseases |
| Research methods | LC-MS/MS, membrane vesicles, Xenopus oocyte expression, CRISPR knockout/knock-in models |
What Is GO:0051958?
GO:0051958 methotrexate transport is defined as the directed movement of methotrexate, 4-amino-10-methylformic acid, into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. Methotrexate is a folic acid analogue and a potent competitive inhibitor of dihydrofolate reductase.
Why Is methotrexate transport Important in Cell Biology?
Methotrexate transport is a critical determinant of drug efficacy and resistance. Because methotrexate cannot passively diffuse across membranes, its intracellular concentration depends on the balance of influx and efflux transporters. Alterations in these transporters can lead to methotrexate resistance in cancer cells, a major clinical challenge. In inflammatory diseases such as rheumatoid arthritis, transport variability affects both therapeutic response and toxicity. Thus, understanding methotrexate transport at the molecular level is essential for optimizing treatment and developing new therapeutic strategies.
• Determines intracellular methotrexate levels and thus cytotoxicity in cancer cells.
• Impaired transport is a well-documented mechanism of methotrexate resistance in leukemia and solid tumors.
• Transport activity influences methotrexate efficacy in autoimmune and inflammatory diseases like rheumatoid arthritis.
• Reduced folate carrier (SLC19A1) is the major influx transporter for methotrexate in many tissues.
• ABC transporters such as MRP1-5 mediate methotrexate efflux and contribute to drug resistance.
• Folate receptors can mediate methotrexate uptake in specific cell types, offering targeted delivery opportunities.
• Methotrexate transport is studied using diverse models including human cancer cell lines, Xenopus oocytes, and membrane vesicles.
• Genetic variation in transporters may predict clinical response to methotrexate.
• CRISPR-based editing enables functional dissection of individual transporters in methotrexate transport.
• Understanding transport mechanisms can guide the development of transporter-targeted therapies.
What Happens During methotrexate transport?
Influx via the Reduced Folate Carrier (RFC/SLC19A1)
In simple terms: Methotrexate enters cells mainly through a dedicated carrier protein called RFC.
The reduced folate carrier (RFC, encoded by SLC19A1) is the primary influx transporter for methotrexate in many cell types. It is a transmembrane protein that mediates the uphill transport of reduced folates and methotrexate in exchange for organic anions. Studies in human distal lung epithelial NCl-H441 cells demonstrated RFC-mediated methotrexate transport with characteristic kinetics. In LNCaP human prostate cancer cells, methotrexate uptake was also shown to be carrier-mediated. RFC expression levels correlate with methotrexate sensitivity, and loss of RFC function is a common cause of resistance.
Efflux via ATP-Binding Cassette (ABC) Transporters
In simple terms: Methotrexate can be pumped out of cells by ABC transporters, reducing its effectiveness.
ATP-binding cassette (ABC) transporters, particularly multidrug resistance-associated proteins (MRPs/ABCCs), mediate the efflux of methotrexate and its polyglutamated forms. MRP1 (ABCC1) and MRP2 (ABCC2) are known to transport methotrexate, contributing to drug resistance. In Drosophila, a multidrug resistance-associated protein was shown to transport methotrexate in vitro. Efflux activity lowers intracellular drug concentrations and is a key mechanism of resistance in cancer cells.
Alternative Uptake Routes: Folate Receptors and Organic Anion Transporters
In simple terms: Some cells take up methotrexate through other proteins like folate receptors.
In addition to RFC, folate receptors (e.g., FOLR1, FOLR2) can mediate methotrexate uptake via receptor-mediated endocytosis. This route is particularly relevant for targeted drug delivery, as folate receptors are overexpressed in some cancers. Organic anion transporters (OATs) and organic anion transporting polypeptides (OATPs) may also contribute to methotrexate transport in specific tissues such as the liver and kidney. The relative contribution of each transporter depends on cell type and expression levels.
Transport Kinetics and Substrate Specificity
In simple terms: Transporters have specific preferences and speeds for moving methotrexate.
Methotrexate transport kinetics have been characterized in various systems. In human choriocarcinoma cell lines, LC-MS/MS analysis revealed saturable transport with specific kinetic parameters. Studies using basolateral membrane vesicles from rat liver demonstrated carrier-mediated methotrexate transport with distinct inhibitor sensitivity. The substrate specificity of RFC and MRPs has been mapped, showing competition with folates and other anions. These kinetic properties are critical for predicting drug interactions and resistance profiles.
Regulation of Transporters and Adaptive Responses
In simple terms: Cells can change the number of transporters to adapt to methotrexate exposure.
Transporter expression is regulated at transcriptional and post-transcriptional levels. For example, RFC expression can be modulated by folate status and cellular stress. In some resistant cell lines, decreased RFC expression or increased MRP expression is observed. Additionally, mutations in transporter genes can alter substrate specificity or transport efficiency. These adaptive changes contribute to acquired resistance and are targets for therapeutic intervention.
Key Genes Involved in GO:0051958 methotrexate transport
The following genes encode proteins that directly mediate or regulate methotrexate transport, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC19A1 | Reduced folate carrier (RFC); primary influx transporter for methotrexate | Major determinant of methotrexate uptake and sensitivity; loss causes resistance |
| ABCC1 | Multidrug resistance-associated protein 1 (MRP1); efflux transporter | Mediates methotrexate efflux and resistance in cancer cells |
| ABCC2 | Multidrug resistance-associated protein 2 (MRP2); efflux transporter | Contributes to methotrexate efflux in liver and kidney |
| ABCC3 | Multidrug resistance-associated protein 3 (MRP3); efflux transporter | May transport methotrexate in specific tissues |
| ABCC4 | Multidrug resistance-associated protein 4 (MRP4); efflux transporter | Implicated in methotrexate efflux and resistance |
| ABCC5 | Multidrug resistance-associated protein 5 (MRP5); efflux transporter | Can transport methotrexate and folate analogues |
| FOLR1 | Folate receptor alpha; mediates methotrexate uptake via endocytosis | Target for folate-receptor-specific drug delivery |
| FOLR2 | Folate receptor beta; alternative uptake route | Expressed in placenta and some cancers; potential delivery target |
| SLC22A6 | Organic anion transporter 1 (OAT1); renal transport | Influences methotrexate pharmacokinetics and elimination |
| SLC22A8 | Organic anion transporter 3 (OAT3); renal transport | Contributes to methotrexate clearance |
| SLCO1B1 | Organic anion transporting polypeptide 1B1 (OATP1B1); hepatic uptake | Affects methotrexate disposition and toxicity |
| SLCO1B3 | Organic anion transporting polypeptide 1B3 (OATP1B3); hepatic uptake | May influence methotrexate liver uptake |
| ABCG2 | Breast cancer resistance protein (BCRP); efflux transporter | Potential role in methotrexate efflux and resistance |
| DHFR | Dihydrofolate reductase; target of methotrexate | Methotrexate transport determines intracellular access to DHFR |
| FPGS | Folylpolyglutamate synthetase; converts methotrexate to polyglutamates | Polyglutamation traps methotrexate intracellularly and enhances activity |
| GGH | Gamma-glutamyl hydrolase; removes polyglutamates | Modulates methotrexate retention and activity |
How Is methotrexate transport Regulated?
Methotrexate transport is regulated at multiple levels. Transporter gene expression can be induced or repressed by folate status, cellular stress, and drug exposure. For example, RFC (SLC19A1) expression is influenced by folate availability and can be downregulated in methotrexate-resistant cells. Efflux transporters such as MRPs are often upregulated in resistant cells, enhancing drug efflux. Post-translational modifications and trafficking of transporters also modulate their activity. Additionally, genetic polymorphisms in transporter genes can affect transport efficiency and clinical response.
methotrexate transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC19A1 | Methotrexate resistance in leukemia and solid tumors | CRISPR knockout in cancer cell lines (e.g., K562, MCF-7) followed by methotrexate sensitivity assays |
| ABCC1 | Drug resistance in cancer | Overexpression in HEK293 cells and efflux assays |
| FOLR1 | Targeted drug delivery in cancer | Knock-in of FOLR1 in low-expressing cells for uptake studies |
| SLC22A6 | Methotrexate pharmacokinetics and renal toxicity | Knockout in renal epithelial cells or organoids |
| SLCO1B1 | Hepatic uptake and methotrexate toxicity | Point mutation knock-in in hepatocyte-like cells |
Methotrexate Resistance in Cancer
Impaired methotrexate transport is a major mechanism of resistance in leukemia and solid tumors. Decreased expression or function of the reduced folate carrier (SLC19A1) reduces drug uptake, while increased expression of efflux transporters such as MRP1 (ABCC1) enhances drug removal. These changes lower intracellular methotrexate polyglutamate levels, diminishing inhibition of dihydrofolate reductase and other folate-dependent enzymes. Understanding transport defects can guide strategies to overcome resistance, such as using lipophilic antifolates or transporter-targeted delivery.
Rheumatoid Arthritis and Inflammatory Diseases
Methotrexate is a first-line therapy for rheumatoid arthritis and other inflammatory conditions. Variability in transport mechanisms, including RFC and folate receptor-mediated uptake, influences drug efficacy and toxicity. Genetic polymorphisms in SLC19A1 and other transporters have been associated with clinical response. Targeting specific transport pathways, such as folate receptor-mediated delivery, may improve therapeutic outcomes and reduce side effects.
Transport in Normal Tissues and Toxicity
Methotrexate transport in normal tissues affects drug distribution and toxicity. Renal tubular secretion via organic anion transporters (OATs) and hepatic uptake via OATPs influence methotrexate clearance. Impaired transport in these organs can lead to increased systemic exposure and toxicity. Understanding tissue-specific transport is important for predicting drug interactions and individualizing therapy.
From methotrexate transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC19A1 reduce methotrexate uptake? | CRISPR knockout of SLC19A1 in HeLa or K562 cells, followed by LC-MS/MS uptake assays |
| Does a specific SLC19A1 mutation alter transport kinetics? | Point mutation knock-in of SLC19A1 in a null background, followed by kinetic analysis |
| Can overexpression of ABCC1 confer methotrexate resistance? | Overexpression of ABCC1 in HEK293 cells, followed by cytotoxicity assays |
| Does FOLR1 mediate methotrexate uptake via endocytosis? | Knock-in of FOLR1 with a fluorescent tag in CHO cells, followed by imaging |
| What is the role of MRP4 in methotrexate efflux? | CRISPR knockout of ABCC4 in cancer cells, followed by efflux assays |
| Can a tagged transporter be used to study localization? | Tagged knock-in of SLC19A1 with GFP in a cancer cell line, followed by live-cell imaging |
How to Study the methotrexate transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS | Intracellular and extracellular methotrexate concentrations | Quantifying transport kinetics in cell lines |
| Membrane vesicle assay | Transporter-mediated uptake into vesicles | Characterizing transport in isolated membranes |
| Xenopus oocyte expression | Transport activity of individual transporters | Functional characterization of cloned transporters |
| CRISPR knockout screen | Genes affecting methotrexate sensitivity | Identifying novel transport regulators |
| Radiolabeled methotrexate uptake | Influx rate and inhibitor profile | Kinetic studies in cell lines |
| Efflux assay | Drug efflux activity | Measuring ABC transporter function |
| Live-cell imaging | Transporter localization and trafficking | Studying tagged transporters in real time |
| RNA-seq | Transporter gene expression changes | Profiling resistance mechanisms |
LC-MS/MS for Quantifying Methotrexate Transport
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a highly sensitive method for measuring intracellular and extracellular methotrexate concentrations. It has been used to evaluate transport mechanisms in human choriocarcinoma cell lines, providing precise kinetic data. This method is ideal for quantifying transport activity in CRISPR-edited cells.
Membrane Vesicle Transport Assays
Membrane vesicles prepared from cells or tissues can be used to study transporter-mediated methotrexate uptake. This system allows direct measurement of transport activity independent of cellular metabolism. It has been applied to basolateral membrane vesicles from rat liver to characterize methotrexate transport.
Xenopus Oocyte Expression System
Xenopus oocytes microinjected with transporter cRNA are a powerful tool for studying individual transport proteins. This system has been used to characterize methotrexate transport by Drosophila MRP and mammalian transporters. It enables precise control of transporter expression and electrophysiological or radiotracer-based assays.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate methotrexate transport and sensitivity. Cells are transduced with a library, selected with methotrexate, and sgRNAs enriched or depleted are identified by sequencing. This approach can uncover novel transporters and resistance mechanisms.
How CRISPR Can Be Used to Study GO:0051958 methotrexate transport
Knockout
CRISPR knockout of candidate transporters such as SLC19A1 or ABCC1 allows direct testing of their role in methotrexate transport. Cells with specific gene knockouts can be compared to wild-type for methotrexate uptake, efflux, and cytotoxicity. This approach is essential for establishing causal relationships between transporter expression and drug response.
Point Mutation
Point mutation knock-in can model clinically relevant polymorphisms or resistance mutations in transporter genes. For example, mutations in SLC19A1 that alter substrate specificity can be introduced into a null background to study their impact on methotrexate transport kinetics. This enables precise structure-function analysis.
Knock-in
Knock-in of tagged transporters (e.g., GFP-SLC19A1) allows visualization of transporter localization and trafficking in live cells. Knock-in of reporter genes under transporter promoters can be used to study transcriptional regulation. These models are valuable for understanding dynamic transport processes.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can be used to increase expression of specific transporters. Overexpression of efflux transporters like ABCC1 can confer methotrexate resistance, providing a model to study resistance mechanisms. Conversely, overexpression of influx transporters can enhance sensitivity.
How EDITGENE Supports methotrexate transport Research
Researchers studying methotrexate transport-related genes often need to determine whether a candidate gene is causally involved in drug uptake, efflux, or resistance. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for methotrexate transport research.
Frequently Asked Questions About methotrexate transport
What is methotrexate transport (GO:0051958)?
Methotrexate transport is the directed movement of methotrexate into, out of, or within a cell, mediated by transporters or pores.
What genes are involved in methotrexate transport?
Key genes include SLC19A1 (reduced folate carrier), ABCC1-5 (MRPs), FOLR1/2 (folate receptors), and SLC22A6/8 (organic anion transporters).
How does methotrexate enter cells?
Methotrexate primarily enters cells via the reduced folate carrier (SLC19A1) and can also be taken up by folate receptors.
What causes methotrexate resistance related to transport?
Decreased uptake due to loss of SLC19A1 or increased efflux via ABC transporters such as MRP1 can cause resistance.
Which transporters efflux methotrexate?
MRP1 (ABCC1), MRP2 (ABCC2), and other ABC transporters mediate methotrexate efflux.
How is methotrexate transport studied experimentally?
Common methods include LC-MS/MS, membrane vesicle assays, Xenopus oocyte expression, and CRISPR-based screens.
What is the role of SLC19A1 in methotrexate transport?
SLC19A1 encodes the reduced folate carrier, the major influx transporter for methotrexate in many cells.
Can CRISPR be used to study methotrexate transport?
Yes, CRISPR knockout, knock-in, and overexpression models enable functional dissection of specific transporters.
What diseases are linked to methotrexate transport?
Cancer drug resistance and rheumatoid arthritis are major areas where transport affects treatment response.
What are the clinical implications of methotrexate transport?
Transport activity determines drug efficacy and toxicity, influencing dosing and resistance in patients.
Conclusion
GO:0051958 methotrexate transport is a fundamental biological process that governs the cellular pharmacokinetics of a widely used therapeutic agent. The interplay between influx transporters like SLC19A1 and efflux pumps such as MRPs determines intracellular drug levels and clinical outcomes. Understanding these mechanisms is crucial for overcoming resistance and optimizing methotrexate therapy. CRISPR-based models provide powerful tools to dissect the specific roles of individual transporters and identify novel regulators of methotrexate transport. EDITGENE offers comprehensive services to support such research, from knockout and knock-in cell lines to library screening and bioinformatics analysis.
References
- 1. Moscow JA. 1998. Methotrexate transport and resistance.. Leuk Lymphoma 30(3-4):215-24 PMID: 9713954
- 2. Fiehn C. 2010. Methotrexate transport mechanisms: the basis for targeted drug delivery and ß-folate-receptor-specific treatment.. Clin Exp Rheumatol 28(5 Suppl 61):S40-5 PMID: 21044432
- 3. Bai M et al.. 2024. Evaluation of transport mechanisms of methotrexate in human choriocarcinoma cell lines by LC-MS/MS.. J Pharm Biomed Anal 247:116268 PMID: 38823222
- 4. Karasik A et al.. 2018. In vitro transport of methotrexate by Drosophila Multidrug Resistance-associated Protein.. PLoS One 13(10):e0205657 PMID: 30312334
- 5. Kawami M et al.. 2019. Reduced folate carrier-mediated methotrexate transport in human distal lung epithelial NCl-H441 cells.. J Pharm Pharmacol 71(2):167-175 PMID: 30324648
- 6. Horne DW et al.. 2002. Transport of methotrexate into LNCaP human prostate cancer cells.. Biofactors 16(1-2):19-27 PMID: 12515913
- 7. Horne DW et al.. 1992. Transport of methotrexate in basolateral membrane vesicles from rat liver.. Arch Biochem Biophys 298(1):121-8 PMID: 1524420
- 8. Matherly LH et al.. 2003. Membrane transport of folates.. Vitam Horm 66:403-56 PMID: 12852262
